What We Do

For 140 years, we have worked tirelessly to develop and deliver trusted medicines that meet real needs. We focus our internal research efforts primarily on four core therapeutic areas: specialty care, diabetes, oncology and animal health. We also continue to pursue innovative science and new opportunities beyond our targeted disease categories.

Specialty Care

Specialty Care includes the therapeutic areas of neuroscience, cardiovascular, urology and musculoskeletal medicine.  Some of our most recent research has focused on immunotherapy and has delivered new treatments in dermatology and rheumatology.

Lilly has a strong heritage in mental health and has discovered treatments for a range of conditions, including depression, schizophrenia, ADHD and bi-polar disorder. We have been searching for a better understanding of new treatments for Alzheimer’s disease for 30 years and our pipeline includes therapeutics and diagnostics that target the two known hallmarks of Alzheimer’s disease – amyloid beta and tau tangles, as well as potential new treatments for pain, migraine and cluster headaches.


Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. More than ninety years later, we remain committed to meeting the needs of people with diabetes, from medicines to support programmes and more.

Lilly understands that people with diabetes are individuals. Many of our programmes and solutions are therefore designed based on feedback from people who live with the disease every day. We also understand that fighting the growing diabetes epidemic goes beyond the capabilities of any one company. Lilly Diabetes’ donation of insulin vials to the Life for a Child programme and our educational grant in support of the International Diabetes Federation's Bridges programme which supports translational research in local communities, and our work with the Juvenile Diabetes Research Foundation (JDRF) represent just a few examples of our long-term commitment to diabetes care.


Lilly Oncology focuses on advancing innovation and improving outcomes for individual patients, and boasts one of the largest clinical pipelines in the oncology industry.

The term cancer refers to a class of diseases in which a group of cells begin to grow uncontrollably and invade and destroy adjacent tissues. Sometimes, the cancerous cells spread to other parts of the body through the lymph system or through our blood – a process known as metastasis. Most cancerous cells form a tumour or tumours while some, like leukemia, do not.

For more than five decades, Lilly has been dedicated to delivering innovative solutions that accelerate the pace and progress of cancer care and enhance the lives of people living with cancer.

Through our ongoing research efforts around the world, we invest significant resources in these products to help meet unmet medical needs, to better understand how our medicines work and to find out which patients are most likely to benefit from them.


Elanco Animal Health

A global division of Lilly, Elanco works to develop and market products that improve animal health and protein production in more than 75 countries across the globe. Find out more


Lilly R&D

Lilly Research Laboratories (LRL) discovers and develops high- quality innovative medicines that help patients live longer, healthier, happier lives. Find out more